A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer (NCT02716116)
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
Who can join: Review the eligibility criteria below.
Location: Brookwood Medical Center — Birmingham, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- Brookwood Medical Center — Birmingham, Alabama
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- The Oncology Institute of Hope and Innovation - West Tucson — Tucson, Arizona
- City of Hope Comprehensive Cancer Center - Duarte — Duarte, California
- Compassionate Cancer Care - Fountain Valley — Fountain Valley, California
- University of California San Diego Moores Cancer Center — La Jolla, California
- Pacific Shores Medical Group-Long Beach Elm — Long Beach, California
- Cancer and Blood Specialty Clinic — Los Alamitos, California
- University of California Irvine Health Chao Family Comprehensive Cancer Center — Orange, California
- Stanford Cancer Center - Palo Alto — Palo Alto, California
- SLO Oncology and Hematology Health Center — San Luis Obispo, California
- The Oncology Institute of Hope and Innovation — Whittier, California
- University of Colorado Cancer Center — Aurora, Colorado
- AdventHealth Orlando — Orlando, Florida
- Winship Cancer Institute — Atlanta, Georgia
- The University of Chicago Medicine — Chicago, Illinois
- Investigative Clinical Research - Indiana — Indianapolis, Indiana
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute — Boston, Massachusetts
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Siteman Cancer Center - Washington University Medical Campus — St Louis, Missouri
- Atlantic Health - Morristown Medical Center — Morristown, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.